A.D.A.M. Innovations and SOPHiA GENETICS Partner to Revolutionize Liquid Biopsy Testing in Japan

A.D.A.M. Innovations and SOPHiA GENETICS Team Up for Liquid Biopsy Advancements in Japan

A.D.A.M. Innovations, a leading private genetic testing company in Japan, has announced a strategic partnership with SOPHiA GENETICS, a pioneering AI technology firm focused on data-driven medicine. This collaboration aims to make advanced genomic liquid biopsy testing available to the Japanese population, significantly influencing the field of precision oncology.

During the recent ESMO Congress, the two companies unveiled their commitment to delivering innovative liquid biopsy solutions that focus on both testing and companion diagnostic applications. As a market leader in genetic testing, A.D.A.M. has conducted over 2.8 million genomic tests in its state-of-the-art laboratory located in Tokyo, contributing to the local healthcare landscape for more than 20 years.

The initial focus of this partnership will be on introducing the liquid biopsy application MSK-ACCESS® on the SOPHiA DDM™ platform. This cutting-edge test is engineered to detect genomic alterations through a single blood draw, employing advanced artificial intelligence to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test is characterized by a well-coordinated tumor-normal comparison approach that enhances accuracy and reduces false positive results.

By performing tests and analyzing samples in-house, A.D.A.M. Innovations is set to expedite turnaround times, reduce costs for patients, and bolster local cancer research efforts. This local testing capacity is crucial as it aims to improve access to high-quality tumor profiling, an essential aspect of personalized medicine that is increasingly important in today's healthcare environment.

In addition to introducing MSK-ACCESS®, the partnership plans to develop a Companion Diagnostic (CDx) test for liquid biopsies to further enhance access to these vital diagnostic capabilities. By evolving the application into a CDx test, more patients in Japan will benefit from high-quality tumor profiling tests, facilitating a more personalized approach to treatment. This offering will provide pharmaceutical partners with a powerful tool to accelerate drug development and market access efforts in the region.

As the companies embark on the development journey, A.D.A.M.'s extensive clinical and regulatory expertise will play a pivotal role in supporting the approval processes in Japan. “Making precision oncology accessible to patients in Japan marks a significant milestone. The combination of A.D.A.M. Innovations' strong clinical expertise and local presence with the global reach of the SOPHiA DDM™ platform enables us to drive the nationwide rollout of data-driven medicine,” stated Ross Muken, President of SOPHiA GENETICS.

Furthermore, Michel Mommejat, President of A.D.A.M. Innovations, emphasized the importance of this partnership, noting, “For over two decades, we have been providing advanced clinical genomic testing to academic, research, and medical institutions. Our alliance with SOPHiA GENETICS and their AI-driven platform represents a significant leap towards accelerating precision oncology in Japan. Local testing allows for quicker turnaround times, reduced costs, and enhanced patient care, thereby supporting the global deployment of CDx.”

This fruitful collaboration was officially announced at the European Society for Medical Oncology Congress 2025 in Berlin. The announcement highlights the dedication of both companies to advance data-driven, liquid biopsy-based solutions for cancer treatment in Japan. Attendees can learn more about their initiatives by visiting the SOPHiA GENETICS and A.D.A.M. Innovations booth (#2039) between October 17 and 21, 2025.

To gain further insights about SOPHiA GENETICS, visit SOPHiAGENETICS.COM or connect with them on LinkedIn. For details about A.D.A.M. Innovations, check out ADAM-INNOVATIONS.COM or connect on LinkedIn.

SOPHiA GENETICS is a cloud-native health technology company dedicated to expanding access to data-driven medicine using AI, offering top-tier care to patients with cancer and rare diseases worldwide. The company’s SOPHiA DDM™ platform analyzes complex genomic and multimodal data, generating actionable insights in real-time for a broad global network of hospitals, laboratories, and biopharmaceutical entities.

Note that the products from SOPHiA GENETICS are intended for research purposes only and should not be used for diagnostic procedures unless explicitly stated otherwise. Information in this announcement may refer to products that might not be available in all countries or may not have been approved by regulatory authorities for various applications. Please reach out to [email protected] for product information applicable to your residence.

The press release includes forward-looking statements which express the intentions, beliefs, and expectations concerning future operations and performance. Actual results may differ due to various factors, including those outlined in documentation submitted to the U.S. Securities and Exchange Commission (SEC). Such statements are subject to risks and uncertainties and do not constitute promises or guarantees.